TKT

Across TCGA pan-cancer cohorts, TKT Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TKT data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher TKT Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TKT expression acts as an unfavorable survival marker.

ACC, LIHC, and PAAD are the cancer types where TKT Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.185	0.811	<.001	30	view →
LIHC	DFS	Median	All	0.026	0.556	<.001	18	view →
PAAD	DFS	Median	All	0.100	0.484	.003	12	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	6	view →
HNSC	DFS	Median	IV	0.128	0.669	.011	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TKT–ACC (OS)

Open the ACC breakdown →